Point of Care Molecular Diagnostics Market

Point of Care Molecular Diagnostics Market by Product (Assays, Kits, Instruments, Software), Application (Respiratory Diseases, HAIs, Cancer, STDs, Hepatitis), Technology (RT-PCR, INAAT), End User (Clinics, Hospitals, ICUs) & Region - Global Forecast to 2028

Report Code: MD 6292 Jun, 2023, by marketsandmarkets.com

The global point of care molecular diagnostics market in terms of revenue was estimated to be worth $2.0 billion in 2023 and is poised to reach $3.4 billion by 2028, growing at a CAGR of 10.6% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is mainly driven by rising incidence of infectious diseases and acute and chronic conditions and increased focus on improving the state of healthcare facilities and infrastructure. However, the market entry of several firms has been resisted by uncertain reimbursement circumstances. The market's expansion is further constrained by a shortage of high-complexity testing facilities that can perform POC molecular diagnostics testing.

Point of Care Molecular Diagnostics Market

To know about the assumptions considered for the study, Request for Free Sample Report

Point of Care Molecular Diagnostics Market

Point of Care Molecular Diagnostics Market Dynamics

Driver: Growing incidence of infectious diseases and cancer

The rising occurrence of infectious diseases and cancer in both developed and developing regions is set to have a favourable impact on the expansion of the point-of-care molecular diagnostics market. The diagnosis and treatment of these diseases necessitate an increasing number of molecular diagnostic tests, leading to a surge in the demand for such tests. Moreover, the growing inclination towards preventive medicine further contributes to the anticipated rise in demand for point-of-care molecular diagnostics throughout the forecast period.

Restraint: Unfavourable reimbursement settings

The growth of the point-of-care molecular diagnostics market is hindered by inadequate reimbursements. One of the significant challenges faced by diagnostic companies is obtaining payment from Medicare and private health insurers for their tests. In the United States, Medicare revised its reimbursement mechanism for certain in vitro diagnostic (IVD) tests, including point-of-care molecular tests, in 2018. Some of these tests lack specific Healthcare Common Procedure Coding System (HCPCS) codes and are billed using unlisted codes instead. In such cases, payment amounts are established by Medicare Administrative Contractors (MACs) for their respective jurisdictions. Additionally, Medicare currently does not provide coverage for genetic testing in individuals without a personal history of cancer, as indicated by the American Society of Clinical Oncology. These factors are anticipated to have an adverse impact on the point-of-care molecular testing market.

Opportunity: Growth prospects in emerging countries

Players in the point-of-care molecular diagnostics market have substantial growth prospects in emerging economies like India, South Korea, Brazil, and Mexico. These opportunities stem from several factors, including relatively low regulatory barriers, advancements in healthcare infrastructure, expanding patient populations, increasing incidence of infectious diseases, and a rise in healthcare expenditure. Additionally, the regulatory policies in some of these countries are more flexible and conducive to business compared to those in developed nations.

Challenge: Establishment of alternative technologies

The emergence of alternative technologies, including those employed in COVID-19 testing, presents a potential obstacle to the growth of the point-of-care molecular diagnostics market . Most diagnostic tests can be divided into serological and antigen tests and these tests result is usually available in 15 minutes, and thus they are commonly referred to as rapid tests. Antigen tests are also cheaper to manufacture than molecular tests owing to their simpler design. Thus, the introduction of alternative technologies might be challenging to the growth of the point-of-care molecular diagnostics market.

Point of Care Molecular Diagnostics Market Ecosystem

Prominent companies in this market include well-established, financially stable manufacturers of point of care molecular assay and kits. These companies have been operating in the market for several years and possess state-of-the-art technologies, diversified product portfolio, strong global sales, and marketing networks. Prominent companies in this market include Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Danaher Corporation (US), and QIAGEN N.V. (Netherlands).

Point of Care Molecular Diagnostics Market Ecosystem

In 2022, assays & kits segment accounted for the largest share of the point of care molecular diagnostics industry, by product & service

Based on product, the point of care molecular diagnostics market is segmented into instruments & analyzers, and software & services. In 2022, the assays & kits segment accounted for the largest share of this market. The frequent purchase of these products due to their recurrent usage drives the market growth of this segment.

In 2022, RT-PCR segment accounted for the largest share in the point of care molecular diagnostics industry, by technology

The point of care molecular diagnostics market is segmented into RT-PCR, INAAT and other technologies based on technology. In 2022, the RT-PCR segment accounted for the largest share. RT-PCR is one of the most widely used technologies in diagnostics due to its ease of use, cost-effectiveness, and prompt turnaround time (4 to 6 hours).

In 2022, Physicians’ offices segment accounted for the largest share in the point of care molecular diagnostics industry, by end user

Based on end users, the point of care molecular diagnostics market is segmented into physicians’ offices, hospitals & ICUs, research institutes, and other end users. In 2022, the physicians’ offices segment accounted for the largest share of the point-of-care molecular diagnostics market. Point-of-care molecular assay & kits and systems are extensively used in physicians’ offices as they provide quick results within 30 minutes. This helps in instant diagnosis which allows to diagnose or monitor a patient’s condition immediately.

North America is the largest region of the point of care molecular diagnostics industry

The global point of care molecular diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2022, North America accounted for the largest share of the global point-of-care molecular diagnostics market. The high burden of infectious diseases and cancers on regional healthcare systems is one of the major drivers for market growth. Furthermore, the presence of a well-developed healthcare infrastructure and the growing adoption of advanced technologies infectious disease testing are other factors anticipated to support the growth of the point-of-care molecular diagnostics market in the region.

Point of Care Molecular Diagnostics Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The major players in this market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Danaher Corporation (US), and QIAGEN N.V. (Netherlands). These players lead the market because of their extensive product portfolios and wide geographic presence. These dominant market players also have numerous advantages, such as more robust marketing and distribution networks, larger budgets for R&D, and better brand recognition.

Scope of the Point of Care Molecular Diagnostics Industry

Report Metric 

Details 

Market Revenue in 2023

$2.0 billion

Projected Revenue by 2028

$3.4 billion

Revenue Rate

poised to grow at a CAGR of 10.6%

Growth Driver

Growing incidence of infectious diseases and cancer

Growth Opportunity

Growth prospects in emerging countries

This report categorizes the point of care molecular diagnostics market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

  • Assays & kits
  • Instruments & Analyzers
  • Software & Services

By Technology

  • RT-PCR
  • INAAT
  • Other technologies

By Application

  • Respiratory Diseases
  • Sexually Transmitted Diseases
  • Hospital-acquired Infections
  • Cancer
  • Hepatitis
  • Gastrointestinal Disorders
  • Other Applications

By End User

  • Physicians’ Offices
  • Hospitals & ICUs
  • Research Institutes
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Rest of Europe (RoE)
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific (RoAPAC)
  • Rest of the World (RoW)

Recent Developments of Point of Care Molecular Diagnostics Industry

  • In April 2023, QIAGEN N.V. (Netherlands) launched QIAstat-Dx in Japan with a respiratory panel for syndromic testing.
  • In June 2022, Biocartis NV (Belgium) launched the Rapid CE-marked IVD Idylla GeneFusion Panel for fast treatment decisions in lung cancer.
  • In May 2022, bioMérieux SA (France) received De Novo FDA Authorization for its BIOFIRE Joint Infection (JI) Panel.
  • In September 2021, F. Hoffmann-La Roche Ltd. (Switzerland) acquired TIB Molbiol (Germany) to expand its PCR test portfolio with a wide range of assays for infectious diseases.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 28)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKETS COVERED 
           1.3.1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION
           1.3.2 GEOGRAPHIC SCOPE
           1.3.3 YEARS CONSIDERED
    1.4 CURRENCY 
    1.5 STUDY LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
           1.7.1 RECESSION IMPACT
 
2 RESEARCH METHODOLOGY (Page No. - 33)
    2.1 RESEARCH DATA 
    2.2 RESEARCH APPROACH 
          FIGURE 1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    2.2.2.1 Primary sources
                    2.2.2.2 Key data from primary sources
                    2.2.2.3 Key industry insights
                    2.2.2.4 Breakdown of primary interviews
                                FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.3 MARKET SIZE ESTIMATION 
           2.3.1 BOTTOM-UP APPROACH
                    2.3.1.1 Approach 1: Company revenue estimation approach
                                FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
                    2.3.1.2 Approach 2: Presentations of companies and primary interviews
                    2.3.1.3 Growth forecast
                    2.3.1.4 CAGR projections
                                FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.3.2 TOP-DOWN APPROACH
                    FIGURE 6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN & DATA TRIANGULATION 
          FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.5 MARKET SHARE ANALYSIS 
    2.6 STUDY ASSUMPTIONS 
    2.7 LIMITATIONS 
    2.8 RISK ASSESSMENT 
           2.8.1 RISK ASSESSMENT: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
    2.9 RECESSION IMPACT: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET 
 
3 EXECUTIVE SUMMARY (Page No. - 47)
    FIGURE 8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    FIGURE 9 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    FIGURE 10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
 
4 PREMIUM INSIGHTS (Page No. - 51)
    4.1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET OVERVIEW 
          FIGURE 13 RISING ADOPTION OF POC DIAGNOSTICS TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD
    4.2 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE, 2023 VS. 2028 
          FIGURE 14 ASSAYS & KITS SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028
    4.3 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 2023 VS. 2028 
          FIGURE 15 RT-PCR SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
    4.4 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY APPLICATION, 2023 VS. 2028 
          FIGURE 16 RESPIRATORY DISEASES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
    4.5 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USER, 2023 VS. 2028 
          FIGURE 17 PHYSICIANS’ OFFICES SEGMENT TO CONTINUE TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
    4.6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 54)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 19 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing prevalence of infectious diseases and cancer
                    5.2.1.2 Rising focus on decentralized diagnostics and increasing R&D funding
                    5.2.1.3 Growing awareness of the early detection of infectious diseases
                    5.2.1.4 Increasing use of POC diagnostic tests
           5.2.2 RESTRAINTS
                    5.2.2.1 Unfavorable reimbursement scenario
                    5.2.2.2 High capital investments and low cost-benefit ratio
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growing R&D activities in point-of-care molecular diagnostics testing
                    5.2.3.2 Growth opportunities in emerging economies
           5.2.4 CHALLENGES
                    5.2.4.1 Stringent and time-consuming regulatory policies that significantly increase product launch cycle
                    5.2.4.2 Introduction of alternative technologies
    5.3 PRICING ANALYSIS 
          TABLE 1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT
    5.4 PATENT ANALYSIS 
          FIGURE 20 PATENT ANALYSIS FOR POINT-OF-CARE MOLECULAR DIAGNOSTICS (JANUARY 2013–DECEMBER 2022)
           5.4.1 LIST OF KEY PATENTS
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASE
    5.6 SUPPLY CHAIN ANALYSIS 
          FIGURE 22 POINT-OF-CARE MOLECULAR DIAGNOSTICS: SUPPLY CHAIN ANALYSIS
    5.7 ECOSYSTEM ANALYSIS 
          FIGURE 23 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
           5.7.1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
    5.8 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 2 PORTER’S FIVE FORCES ANALYSIS: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
           5.8.1 THREAT OF NEW ENTRANTS
           5.8.2 THREAT OF SUBSTITUTES
           5.8.3 BARGAINING POWER OF SUPPLIERS
           5.8.4 BARGAINING POWER OF BUYERS
           5.8.5 INTENSITY OF COMPETITIVE RIVALRY
    5.9 PESTLE ANALYSIS 
    5.10 REGULATORY ANALYSIS 
           TABLE 3 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           TABLE 4 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           TABLE 5 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           TABLE 6 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    5.10.1.1 North America
                               5.10.1.1.1 US
                               5.10.1.1.2 Canada
                    5.10.1.2 Europe
                    5.10.1.3 Asia Pacific
                               5.10.1.3.1 China
                               5.10.1.3.2 Japan
                               5.10.1.3.3 India
                    5.10.1.4 Latin America
                               5.10.1.4.1 Brazil
                               5.10.1.4.2 Mexico
                    5.10.1.5 Middle East
                    5.10.1.6 Africa
    5.11 TRADE ANALYSIS 
           TABLE 8 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
           TABLE 9 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
    5.12 TECHNOLOGY ANALYSIS 
    5.13 KEY CONFERENCES AND EVENTS, 2023–2024 
           TABLE 10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS
    5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
           FIGURE 24 REVENUE SHIFT IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
    5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT-OF-CARE MOLECULAR DIAGNOSTICS PRODUCTS
                     TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT-OF-CARE MOLECULAR DIAGNOSTICS PRODUCTS
           5.15.2 BUYING CRITERIA
                     FIGURE 26 KEY BUYING CRITERIA FOR POINT-OF-CARE MOLECULAR DIAGNOSTICS PRODUCTS
                     TABLE 12 KEY BUYING CRITERIA FOR POINT-OF-CARE MOLECULAR DIAGNOSTIC PRODUCTS
 
6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 78)
    6.1 INTRODUCTION 
          TABLE 13 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
    6.2 ASSAYS & KITS 
           6.2.1 RECURRENT PURCHASES OF ASSAYS & KITS TO DRIVE GROWTH
                    TABLE 14 KEY ASSAYS & KITS AVAILABLE IN MARKET
                    TABLE 15 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY REGION, 2021–2028 (USD MILLION)
    6.3 INSTRUMENTS & ANALYZERS 
           6.3.1 INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE GROWTH IN MARKET
                    TABLE 16 KEY INSTRUMENTS & ANALYZERS AVAILABLE IN MARKET
                    TABLE 17 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY REGION, 2021–2028 (USD MILLION)
    6.4 SOFTWARE & SERVICES 
           6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE DEMAND
                    TABLE 18 KEY SOFTWARE & SERVICES AVAILABLE IN MARKET
                    TABLE 19 POINT-OF-CARE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021–2028 (USD MILLION)
 
7 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 84)
    7.1 INTRODUCTION 
          TABLE 20 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
    7.2 RT-PCR 
           7.2.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
                    TABLE 21 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2021–2028 (USD MILLION)
    7.3 INAAT 
           7.3.1 COST BENEFITS OF INAAT TO BOOST DEMAND
                    TABLE 22 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2021–2028 (USD MILLION)
    7.4 OTHER TECHNOLOGIES 
          TABLE 23 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION)
 
8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (Page No. - 88)
    8.1 INTRODUCTION 
          TABLE 24 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
    8.2 RESPIRATORY DISEASES 
           8.2.1 RISING DEMAND FOR EARLY DIAGNOSIS AND DETECTION OF RESPIRATORY DISEASES TO DRIVE GROWTH
                    TABLE 25 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2021–2028 (USD MILLION)
    8.3 SEXUALLY TRANSMITTED DISEASES 
           8.3.1 TECHNOLOGICAL ADVANCEMENTS FOR DETECTION OF STDS TO FAVOR MARKET GROWTH
                    TABLE 26 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2021–2028 (USD MILLION)
    8.4 HOSPITAL-ACQUIRED INFECTIONS 
           8.4.1 RISING BURDEN OF MRSA TO SUPPORT GROWTH
                    TABLE 27 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021–2028 (USD MILLION)
    8.5 CANCER 
           8.5.1 RISING PREVALENCE OF CANCER AND GROWING FUNDING FOR CANCER RESEARCH TO DRIVE MARKET
                    TABLE 28 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION)
    8.6 HEPATITIS 
           8.6.1 INCREASING CASES OF HEPATITIS AMONG HIGH-RISK SUBGROUP POPULATIONS TO BOOST GROWTH
                    TABLE 29 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2021–2028 (USD MILLION)
    8.7 GASTROINTESTINAL DISORDERS 
           8.7.1 GROWING INCIDENCE OF GASTROINTESTINAL DISORDERS TO PROPEL MARKET
                    TABLE 30 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
    8.8 OTHER APPLICATIONS 
          TABLE 31 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
    8.9 COVID-19 
           8.9.1 DECLINING CASES OF COVID-19 TO HINDER MARKET GROWTH
TABLE 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2021–2028 (USD MILLION)
 
9 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (Page No. - 97)
    9.1 INTRODUCTION 
          TABLE 33 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
    9.2 PHYSICIANS’ OFFICES 
           9.2.1 FASTER RESULTS ASSOCIATED WITH POINT-OF-CARE MOLECULAR ASSAYS TO DRIVE GROWTH
                    TABLE 34 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES, BY REGION, 2021–2028 (USD MILLION)
    9.3 HOSPITALS & ICUS 
          TABLE 35 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 36 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY DISEASE TYPE, 2021–2028 (USD MILLION)
           9.3.1 SEPSIS
                    9.3.1.1 Growing need for quick diagnosis and treatment to favor market growth
           9.3.2 GASTROENTERITIS
                    9.3.2.1 Growing incidence of gastroenteritis cases in emergency departments to propel growth
           9.3.3 MENINGOENCEPHALITIS
                    9.3.3.1 Severity of disease and need for early detection to drive demand
           9.3.4 OTHER DISEASES
    9.4 RESEARCH INSTITUTES 
           9.4.1 INCREASING USE OF POC MOLECULAR DIAGNOSTIC TESTS IN GENOMICS RESEARCH TO CONTRIBUTE TO MARKET GROWTH
                    TABLE 37 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
    9.5 OTHER END USERS 
          TABLE 38 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
 
10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION (Page No. - 104)
     10.1 INTRODUCTION 
             TABLE 39 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             10.2.1 RECESSION IMPACT: NORTH AMERICA
                        FIGURE 27 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
                        TABLE 40 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 41 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 42 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 43 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 44 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.2 US
                        10.2.2.1 Growing prevalence of infectious diseases to drive market
                                      TABLE 45 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 46 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 47 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 48 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.3 CANADA
                        10.2.3.1 Rising government initiatives to propel market growth in coming years
                                      TABLE 49 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 50 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 51 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 52 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.3 EUROPE 
             10.3.1 RECESSION IMPACT: EUROPE
                        TABLE 53 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 54 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 55 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 56 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 57 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.2 GERMANY
                        10.3.2.1 Increasing healthcare expenditure to drive market growth in Germany
                                      TABLE 58 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 59 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 60 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 61 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.3 UK
                        10.3.3.1 Increasing prevalence of infectious diseases to fuel growth
                                      TABLE 62 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 63 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 64 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 65 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.4 FRANCE
                        10.3.4.1 Rising R&D expenditure in France to boost market
                                      TABLE 66 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 67 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 68 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 69 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.5 ITALY
                        10.3.5.1 Adoption of advanced diagnostic technologies to favor growth
                                      TABLE 70 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 71 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 72 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 73 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.6 SPAIN
                        10.3.6.1 Growing demand for genetic testing in Spain to create major growth opportunities for market players
                                      TABLE 74 SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 75 SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 76 SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 77 SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.7 REST OF EUROPE
                        TABLE 78 REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 79 REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 80 REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 81 REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.4 ASIA PACIFIC 
             10.4.1 RECESSION IMPACT: ASIA PACIFIC
                        FIGURE 28 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
                        TABLE 82 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 83 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 84 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 85 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 86 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.2 CHINA
                        10.4.2.1 Growing public access to modern healthcare to drive market growth
                                      TABLE 87 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 88 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 89 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 90 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.3 JAPAN
                        10.4.3.1 Universal healthcare reimbursement policy to drive market growth in Japan
                                      TABLE 91 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 92 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 93 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 94 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.4 INDIA
                        10.4.4.1 Increasing private & public investments in healthcare system to support market growth
                                      TABLE 95 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 96 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 97 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 98 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.5 REST OF ASIA PACIFIC (ROAPAC)
                        TABLE 99 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 100 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 101 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 102 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.5 LATIN AMERICA 
             10.5.1 LOW PER CAPITA HEALTH SPENDING TO RESTRAIN MARKET GROWTH
             10.5.2 RECESSION IMPACT: LATIN AMERICA
                        TABLE 103 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 104 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 105 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 106 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA 
             10.6.1 LACK OF SKILLED RESOURCES TO RESTRICT MARKET GROWTH
             10.6.2 RECESSION IMPACT: MIDDLE EAST & AFRICA
                        TABLE 107 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 108 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 109 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 110 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 147)
     11.1 OVERVIEW 
     11.2 STRATEGIES OF KEY PLAYERS 
             11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
                        TABLE 111 OVERVIEW OF STRATEGIES DEPLOYED BY KEY POINT-OF-CARE MOLECULAR DIAGNOSTICS MANUFACTURING COMPANIES
     11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE 29 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET (2018–2022)
     11.4 MARKET SHARE ANALYSIS 
             FIGURE 30 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022)
             TABLE 112 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE: DEGREE OF COMPETITION
     11.5 COMPANY EVALUATION QUADRANT 
             11.5.1 LIST OF EVALUATED VENDORS
             11.5.2 STARS
             11.5.3 EMERGING LEADERS
             11.5.4 PERVASIVE PLAYERS
             11.5.5 PARTICIPANTS
                        FIGURE 31 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2022
     11.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2022) 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
                        FIGURE 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2022
     11.7 COMPETITIVE BENCHMARKING 
             11.7.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS
                        FIGURE 33 PRODUCT & SERVICE AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
                        TABLE 113 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY REGIONAL FOOTPRINT
                        TABLE 114 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY PRODUCT & SERVICE FOOTPRINT
                        TABLE 115 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
     11.8 COMPETITIVE SCENARIO 
             11.8.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 116 KEY PRODUCT LAUNCHES & APPROVALS
             11.8.2 DEALS
                        TABLE 117 KEY DEALS
 
12 COMPANY PROFILES (Page No. - 159)
     12.1 KEY PLAYERS 
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
             12.1.1 ABBOTT LABORATORIES
                        TABLE 118 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 34 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
             12.1.2 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 119 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
                        FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
             12.1.3 BIOMÉRIEUX SA
                        TABLE 120 BIOMÉRIEUX SA: BUSINESS OVERVIEW
                        FIGURE 36 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2022)
             12.1.4 DANAHER CORPORATION
                        TABLE 121 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
             12.1.5 QIAGEN N.V.
                        TABLE 122 QIAGEN N.V.: BUSINESS OVERVIEW
                        FIGURE 38 QIAGEN N.V.: COMPANY SNAPSHOT (2022)
             12.1.6 QUIDELORTHO CORPORATION
                        TABLE 123 QUIDELORTHO CORPORATION: BUSINESS OVERVIEW
                        FIGURE 39 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
             12.1.7 CO-DIAGNOSTICS, INC.
                        TABLE 124 CO-DIAGNOSTICS INC.: BUSINESS OVERVIEW
                        FIGURE 40 CO-DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022)
             12.1.8 BIOCARTIS NV
                        TABLE 125 BIOCARTIS NV: BUSINESS OVERVIEW
                        FIGURE 41 BIOCARTIS NV: COMPANY SNAPSHOT (2022)
             12.1.9 MERIDIAN BIOSCIENCE, INC.
                        TABLE 126 MERIDIAN BIOSCIENCE, INC.: BUSINESS OVERVIEW
                        FIGURE 42 MERIDIAN BIOSCIENCE, INC.: COMPANY SNAPSHOT (2022)
             12.1.10 THERMO FISHER SCIENTIFIC INC.
                        TABLE 127 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
                        FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
     12.2 OTHER PLAYERS 
             12.2.1 LUCIRA HEALTH, INC.
             12.2.2 CUE HEALTH
             12.2.3 OPGEN, INC.
             12.2.4 BINX HEALTH, INC.
             12.2.5 MOLBIO DIAGNOSTICS PVT. LTD.
             12.2.6 GENOMADIX
             12.2.7 VISBY MEDICAL, INC.
             12.2.8 QUIKPATH PTE. LTD.
             12.2.9 MD-BIO
             12.2.10 QUANTUMDX GROUP LTD.
             12.2.11 AIDIAN OY
             12.2.12 GENESTAT MOLECULAR DIAGNOSTICS, LLC.
             12.2.13 LABSYSTEMS DIAGNOSTICS OY
             12.2.14 AKONNI BIOSYSTEMS
             12.2.15 CURETIS N.V.
 
13 APPENDIX (Page No. - 205)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 AVAILABLE CUSTOMIZATIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

The objective of the study is to analyze the key market dynamics, such as drivers, opportunities, challenges, restraints, and key player strategies. To track company developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships of the leading players, the competitive landscape of the point-of-care molecular diagnostics market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, market breakdown and data triangulation were used.

The four steps involved in estimating the market size are:

Collecting Secondary Data

The secondary research data collection process involves the usage of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), annual reports, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the point-of-care molecular diagnostics market. A database of the key industry leaders was also prepared using secondary research.

Collecting Primary Data

The primary research data was conducted after acquiring knowledge about the point-of-care molecular diagnostics market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such as hospitals & ICUs, diagnostic laboratories, research institutes, research laboratories and home care settings) and supply side (such as included various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing and product development teams, product manufacturers, wholesalers, channel partners, and distributors) across major countries of North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Approximately 40% of the primary interviews were conducted with stakeholders from the demand side, while those from the supply side accounted for the remaining 60%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.

A breakdown of the primary respondents is provided below:

Point of Care Molecular Diagnostics Market Size, and Share

Note 1: *Others include sales managers, marketing managers, and product managers.

Note 2: Tiers are defined based on a company’s total revenue as of 2022: Tier 1=> USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3=< USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

All major product manufacturers offering various point-of-care molecular diagnostics products were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value point-of-care molecular diagnostics market was also split into various segments and subsegments at the region and country level based on:

  • Product mapping of various manufacturers for each type of point-of-care molecular diagnostics market at the regional and country-level 
  • Relative adoption pattern of each point-of-care molecular diagnostics market among key application segments at the regional and/or country-level 
  • Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country-level. 
  • Detailed secondary research to gauge the prevailing market trends at the regional and/or country-level 

Global Point-of-Care Molecular Diagnostics Market Size: Top-Down Approach

Point of Care Molecular Diagnostics Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the point-of-care molecular diagnostics industry.

Market Definition

Point-of-care molecular diagnostics includes various portable point-of-care devices used by healthcare professionals to detect and diagnose various diseases in humans by using techniques to identify and analyze nucleic acids or proteins at the molecular level.

Key Stakeholders

  • Senior Management
  • End User
  • Finance/Procurement Department
  • R&D Department

Report Objectives

  • To define, describe, segment, and forecast the global point-of-care molecular diagnostics market by product & service, technology, application, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, Middle East & Africa
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as acquisitions, product launches and approvals, expansions, and other developments in the point-of-care molecular diagnostics market.
  • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Country Information

  • Point-of-Care Molecular Diagnostics market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific and Rest of the World

Company profiles

  • Additional ten company profiles of players operating in the point-of-care molecular diagnostics market
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 6292
Published ON
Jun, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Point of Care Molecular Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback